1,216 results on '"Hematti, Peiman"'
Search Results
202. The Gut Microbiome Is Shaped By Pre-Transplant Dietary Intake, Damaged By Broad-Spectrum Antibiotic Exposure, and Is Associated with Response to Autologous Stem Cell Transplantation in Patients with Multiple Myeloma
203. Psychological and Physical Function in Allogeneic Hematopoietic Cell Transplant Survivors with Chronic Graft-Versus-Host Disease
204. First Late Effect in Pediatric Survivors with Chronic Graft-Versus-Host Disease Following Hematopoietic Cell Transplantation for Hematologic Malignancy
205. Point of care, bone marrow mononuclear cell therapy in ischemic heart failure patients personalized for cell potency: 12-month feasibility results from CardiAMP heart failure roll-in cohort
206. Cultured cardiac fibroblasts and myofibroblasts express Sushi Containing Domain 2 and assemble a unique fibronectin rich matrix
207. Early T cell Activation Metrics Predict GVHD In A Humanized Mouse Model of Hematopoietic Stem Cell Transplantation
208. Collection of Peripheral Blood Progenitor Cells in One Day is Associated with Decreased Donor Toxicity compared to Two Days in Unrelated Donors
209. Stem Cells as an Emerging Paradigm in Stroke 4: Advancing and Accelerating Preclinical Research
210. Mesenchymal Stromal Cells in Regenerative Medicine: A Perspective
211. Immune profiling of the bone marrow microenvironment in patients with high-risk localized prostate cancer
212. Exosome-educated macrophages and exosomes differentially improve ligament healing
213. Different Human Immune Lineage Compositions Are Generated in Non-Conditioned NBSGW Mice Depending on HSPC Source
214. Extracellular Vesicles as a Novel Therapeutic Option in Liver Transplantation
215. Clinical Applications of Mesenchymal Stem Cell–Biomaterial Constructs for Tissue Reconstruction
216. Immunobiology of Biomaterial/ Mesenchymal Stem Cell Interactions
217. 357 - Outcomes after HLA-Mismatched Unrelated Donor Hematopoietic Stem Cell Transplantation with Post-Transplant Cyclophosphamide for Graft-Vs-Host Disease Prophylaxis: A Systematic Review and Meta-Analysis
218. 155 - Outcomes with Allogeneic Hematopoietic Stemcell Transplantation in NPM1-Mutated Acute Myeloid Leukemia: A Systematic Review And Meta-Analysis
219. 70 - Exosomes from Crx-527 Stimulated MSCs Suppress T Cell Activation and Xenogeneic Gvhd While Preserving GVL
220. MAP3K8 kinase regulates myeloma growth by cell-autonomous and non-autonomous mechanisms involving myeloma-associated monocytes/macrophages
221. Mesenchymal Stem Cells in Hematopoietic Stem Cell Transplantation
222. Genetic marking as an approach to studying in vivo hematopoiesis: progress in the non-human primate model
223. Human Embryonic Stem Cell-Derived Mesenchymal Progenitors: An Overview
224. Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells
225. Human embryonic stem cell–derived mesenchymal stromal cells
226. Comparison of salvage chemotherapy regimens and prognostic significance of minimal residual disease in relapsed/refractory acute myeloid leukemia
227. Abstract 5733: Versican proteolytic fragments (matrikines) synergize with STING agonists to elicit robust anti-tumor CD8+ T cell responses
228. Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide
229. Endothelin-1 reduces catabolic activity of human mesenchymal stem/stromal cells during chondro- and osteo-lineage differentiation
230. Mesenchymal Stromal Cells and Exosomes: Progress and Challenges
231. Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19?
232. Early T Cell Activation Metrics Predict Graft-versus-Host Disease in a Humanized Mouse Model of Hematopoietic Stem Cell Transplantation
233. Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT
234. Abstract B24: A multicellular, microfluidic model of the human bone marrow niche in metastatic cancers
235. Discovering How Heme Controls Genome Function Through Heme-omics
236. Therapeutic Effects of Lyophilized Conditioned-Medium Derived from Corneal Mesenchymal Stromal Cells on Corneal Epithelial Wound Healing
237. Abstract QS26
238. Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemia
239. Incidence, Risk Factors for and Outcomes of Transplant‐Associated Thrombotic Microangiopathy
240. Impact of Antibiotics on Gut Microbiota Diversity and the Results of a Prospective Dietary Assessment in Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation
241. Prevalence and Biobehavioral Predictors of Early and Long-Term Fatigue Following Hematopoietic Stem Cell Transplantation
242. Evaluation of Tumor Vaccine Generation in a Phase II Multicenter Trial of Single Autologous Hematopoietic Cell Transplant (AutoHCT)Followed By Lenalidomide Maintenance for Multiple Myeloma (MM) with or without Vaccination with Dendritic Cell/ Myeloma Fusions (DC/MM fusion vaccine): Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 1401
243. Weighty choices: selecting optimal G-CSF doses for stem cell mobilization to optimize yield
244. Reproducible Derivation and Expansion of Corneal Mesenchymal Stromal Cells for Therapeutic Applications
245. Faculty Opinions recommendation of An acute immune response underlies the benefit of cardiac stem cell therapy.
246. Incidence, Risk Factors, and Outcomes of Patients Who Develop Mucosal Barrier Injury–Laboratory Confirmed Bloodstream Infections in the First 100 Days After Allogeneic Hematopoietic Stem Cell Transplant
247. Comparison of High Doses of Total Body Irradiation in Myeloablative Conditioning before Hematopoietic Cell Transplantation
248. Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Adults with Diffuse Large B-Cell Lymphoma (DLBCL): Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Registry
249. Post-Marketing Use Outcomes of an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, Axicabtagene Ciloleucel (Axi-Cel), for the Treatment of Large B Cell Lymphoma (LBCL) in the United States (US)
250. Versican Proteolytic Fragments (Matrikines) Regulate the Intratumoral Dendritic Cell Milieu In Vivo: Implications for in Situ Tumor Vaccination
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.